英矽智能与瑞博生物宣布签署战略合作协议，双方将整合各自在人工智能药物发现平台与自动化实验室方面的核心优势，旨在为RNA干扰及寡核苷酸疗法的研发提供从早期发现到临床前研究的端到端赋能。
此次合作将依托英矽智能领先的生成式人工智能平台，结合瑞博生物在核酸药物领域的深厚积累与自动化实验能力，共同加速创新疗法的开发进程。双方期望通过这一深度协作，显著提升靶点发现、分子设计及优化等关键环节的效率与成功率，从而推动下一代核酸治疗药物的突破。
英矽智能与瑞博生物宣布签署战略合作协议，双方将整合各自在人工智能药物发现平台与自动化实验室方面的核心优势，旨在为RNA干扰及寡核苷酸疗法的研发提供从早期发现到临床前研究的端到端赋能。
此次合作将依托英矽智能领先的生成式人工智能平台，结合瑞博生物在核酸药物领域的深厚积累与自动化实验能力，共同加速创新疗法的开发进程。双方期望通过这一深度协作，显著提升靶点发现、分子设计及优化等关键环节的效率与成功率，从而推动下一代核酸治疗药物的突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.